BCBS Michigan

Does BCBS Michigan cover Wegovy?

Quick answer · Weight Loss

BCBS Michigan covers Wegovy for weight loss with prior authorization on Employer / Commercial Insurance and ACA Marketplace.

  • Employer / Commercial Insurance: Covered with requirements. BMI of 30 or higher
  • ACA Marketplace: Covered with requirements. BMI of 30 or higher

Last verified June 2, 2026. Policy effective June 1, 2026. Source: prior-authorization-and-step-therapy-guidelines.pdf. How we verify this data →

Check your card for your exact plan →

Wegovy for Weight Loss

What BCBS Michigan requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 12 and older
  • BMI of 30 or higher
  • BMI of 27 or higher with a weight-related condition (HTN, T2DM, and dyslipidemia)
  • BMI at or above the 95th percentile for age and sex

Qualification pathways

You can qualify through any one of these.

Adult - Obesity or Overweight with Comorbidity (Standard Pathway)

All of:

  • Physician attestation of BMI >= 30 kg/m2 (obese) OR BMI >= 27 kg/m2 (overweight) with at least one weight-related comorbidity (hypertension, T2DM, or dyslipidemia)
  • Current baseline weight documented
  • Physician attestation that member will participate in lifestyle modifications (healthy eating, exercise if appropriate)
  • Not to be used in combination with other weight loss products
  • Cannot be used in combination with other GLP-1 agonist-containing products

Adult - Alternative High-BMI Pathway via Teladoc Program

All of:

  • Age >= 18 years old
  • BMI >= 35 kg/m2
  • Documentation of current (within 30 days) baseline weight
  • Documentation of active participation for a minimum of 6 months in a lifestyle modification program (e.g., food diaries documenting caloric deficit or adherence to low calorie/modified diet, OR exercise logs/step counter reports/gym attendance logs/app/fitness tracker showing at least 10,000 steps/day or 150 min/week moderate-intensity activity)
  • Documentation of current active participation in Teladoc Health Weight Management Program
  • Must be prescribed by a PCP or provider with an established relationship with the member, who has seen the member in-person for evaluation and management of overall health

Pediatric - Ages 12 to 17

All of:

  • Age 12 to 17 years
  • BMI >= 95th percentile standardized for age and sex
  • Current baseline weight documented
  • Physician attestation that member will participate in lifestyle modifications (healthy eating, exercise if appropriate)
  • Not to be used in combination with other weight loss products
  • Cannot be used in combination with other GLP-1 agonist-containing products

Documentation to bring

  • Physician attestation of BMI (>= 30 kg/m2 for obesity, or >= 27 kg/m2 with comorbidity, or >= 35 kg/m2 for alternative pathway)
  • Documentation of current baseline weight
  • Physician attestation of member participation in lifestyle modifications (healthy eating, exercise if appropriate)
  • For alternative adult pathway: Documentation of at least 6 months of active participation in a lifestyle modification program (food diaries, exercise logs, step counter reports, gym logs, fitness tracker printouts showing 10,000 steps/day or 150 min/week moderate-intensity activity)
  • For alternative adult pathway: Documentation of current active participation in Teladoc Health Weight Management Program
  • For alternative adult pathway: Confirmation that prescriber is a PCP or established-relationship provider who has seen member in-person
  • For pediatric: Documentation that BMI is >= 95th percentile standardized for age and sex
  • Attestation that medication will not be combined with other weight loss products
  • Attestation that medication will not be combined with other GLP-1 agonist-containing products
  • For continuation (adults): Physician attestation that member maintains >= 5% weight loss from baseline
  • For continuation (adults): Current weight submission
  • For continuation (adults): Attestation of continued active participation in lifestyle modifications
  • For continuation (adults): BMI >= 18.5 kg/m2
  • For continuation (pediatrics): Physician attestation that member maintains >= 1% reduction in BMI from baseline
  • For continuation (pediatrics): Current weight submission
  • For continuation (pediatrics): Attestation of continued active participation in lifestyle modifications
  • For continuation (pediatrics): BMI-for-age percentile >= 5th percentile

Approval and renewal

  • Initial approval: 12 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight, at least 1% reduction in BMI, and For adults (obesity/overweight pathway): 5% weight loss from baseline, current weight submission, attestation of continued active participation in lifestyle modifications, BMI >= 18.5 kg/m2. For pediatrics (ages 12-17): 1% reduction in BMI from baseline, current weight submission, attestation of continued active participation in lifestyle modifications, BMI-for-age percentile >= 5th percentile. Initial BMI/comorbidity and other initial criteria are not explicitly re-verified at continuation. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Cannot be used in combination with other weight loss products
  • Cannot be used in combination with other GLP-1 agonist-containing products

Policy note: The document header states 'NC' (Not Covered) notation appears next to Wegovy and references that coverage criteria is 'determined by group benefit.' This suggests coverage is group-specific and not universally covered under all plans. The NC designation on the document header may indicate it is not covered for all members. Multiple qualification pathways exist including an alternative high-BMI pathway requiring Teladoc Health Weight Management Program participation. The document title states 'March 2019' but the revised date is 06-01-2026, indicating the effective date is June 2026.

Policy effective June 1, 2026 · verified June 2, 2026 · source: prior-authorization-and-step-therapy-guidelines.pdf

ACA Marketplace

Covered with requirements

What you need to qualify

  • Age 12 and older
  • BMI of 30 or higher
  • BMI of 27 or higher with a weight-related condition (HTN, T2DM, and dyslipidemia)
  • BMI at or above the 95th percentile for age and sex

Qualification pathways

You can qualify through any one of these.

Adult - Obesity or Overweight with Comorbidity (Standard Pathway)

All of:

  • Physician attestation of BMI >= 30 kg/m2 (obese) OR BMI >= 27 kg/m2 (overweight) with at least one weight-related comorbidity (hypertension, T2DM, or dyslipidemia)
  • Current baseline weight documented
  • Physician attestation that member will participate in lifestyle modifications (healthy eating, exercise if appropriate)
  • Not to be used in combination with other weight loss products
  • Cannot be used in combination with other GLP-1 agonist-containing products

Adult - Alternative High-BMI Pathway via Teladoc Program

All of:

  • Age >= 18 years old
  • BMI >= 35 kg/m2
  • Documentation of current (within 30 days) baseline weight
  • Documentation of active participation for a minimum of 6 months in a lifestyle modification program (e.g., food diaries documenting caloric deficit or adherence to low calorie/modified diet, OR exercise logs/step counter reports/gym attendance logs/app/fitness tracker showing at least 10,000 steps/day or 150 min/week moderate-intensity activity)
  • Documentation of current active participation in Teladoc Health Weight Management Program
  • Must be prescribed by a PCP or provider with an established relationship with the member, who has seen the member in-person for evaluation and management of overall health

Pediatric - Ages 12 to 17

All of:

  • Age 12 to 17 years
  • BMI >= 95th percentile standardized for age and sex
  • Current baseline weight documented
  • Physician attestation that member will participate in lifestyle modifications (healthy eating, exercise if appropriate)
  • Not to be used in combination with other weight loss products
  • Cannot be used in combination with other GLP-1 agonist-containing products

Documentation to bring

  • Physician attestation of BMI (>= 30 kg/m2 for obesity, or >= 27 kg/m2 with comorbidity, or >= 35 kg/m2 for alternative pathway)
  • Documentation of current baseline weight
  • Physician attestation of member participation in lifestyle modifications (healthy eating, exercise if appropriate)
  • For alternative adult pathway: Documentation of at least 6 months of active participation in a lifestyle modification program (food diaries, exercise logs, step counter reports, gym logs, fitness tracker printouts showing 10,000 steps/day or 150 min/week moderate-intensity activity)
  • For alternative adult pathway: Documentation of current active participation in Teladoc Health Weight Management Program
  • For alternative adult pathway: Confirmation that prescriber is a PCP or established-relationship provider who has seen member in-person
  • For pediatric: Documentation that BMI is >= 95th percentile standardized for age and sex
  • Attestation that medication will not be combined with other weight loss products
  • Attestation that medication will not be combined with other GLP-1 agonist-containing products
  • For continuation (adults): Physician attestation that member maintains >= 5% weight loss from baseline
  • For continuation (adults): Current weight submission
  • For continuation (adults): Attestation of continued active participation in lifestyle modifications
  • For continuation (adults): BMI >= 18.5 kg/m2
  • For continuation (pediatrics): Physician attestation that member maintains >= 1% reduction in BMI from baseline
  • For continuation (pediatrics): Current weight submission
  • For continuation (pediatrics): Attestation of continued active participation in lifestyle modifications
  • For continuation (pediatrics): BMI-for-age percentile >= 5th percentile

Approval and renewal

  • Initial approval: 12 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight, at least 1% reduction in BMI, and For adults (obesity/overweight pathway): 5% weight loss from baseline, current weight submission, attestation of continued active participation in lifestyle modifications, BMI >= 18.5 kg/m2. For pediatrics (ages 12-17): 1% reduction in BMI from baseline, current weight submission, attestation of continued active participation in lifestyle modifications, BMI-for-age percentile >= 5th percentile. Initial BMI/comorbidity and other initial criteria are not explicitly re-verified at continuation. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Cannot be used in combination with other weight loss products
  • Cannot be used in combination with other GLP-1 agonist-containing products

Policy note: The document header states 'NC' (Not Covered) notation appears next to Wegovy and references that coverage criteria is 'determined by group benefit.' This suggests coverage is group-specific and not universally covered under all plans. The NC designation on the document header may indicate it is not covered for all members. Multiple qualification pathways exist including an alternative high-BMI pathway requiring Teladoc Health Weight Management Program participation. The document title states 'March 2019' but the revised date is 06-01-2026, indicating the effective date is June 2026.

Policy effective June 1, 2026 · verified June 2, 2026 · source: prior-authorization-and-step-therapy-guidelines.pdf

Wegovy for Heart Disease Risk Reduction

What BCBS Michigan requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • BMI of 27 or higher with a weight-related condition (CVD)
  • Established cardiovascular disease (established_cardiovascular_disease)

Qualification pathways

You can qualify through any one of these.

CV Risk Reduction in Adults with Established CVD and Obesity/Overweight

All of:

  • Established cardiovascular disease
  • Obesity (BMI >= 30 kg/m2) OR overweight (BMI >= 27 kg/m2)
  • Used in combination with reduced calorie diet and increased physical activity
  • Current baseline weight documented
  • Physician attestation that member will participate in lifestyle modifications
  • Not to be used in combination with other weight loss products
  • Cannot be used in combination with other GLP-1 agonist-containing products

Documentation to bring

  • Documentation of established cardiovascular disease
  • Physician attestation of BMI >= 30 kg/m2 (obese) or >= 27 kg/m2 (overweight)
  • Documentation of current baseline weight
  • Physician attestation of member participation in lifestyle modifications (reduced calorie diet and increased physical activity)
  • Attestation that medication will not be combined with other weight loss products
  • Attestation that medication will not be combined with other GLP-1 agonist-containing products
  • For continuation: Physician attestation that member maintains >= 5% weight loss from baseline
  • For continuation: Current weight submission
  • For continuation: Attestation of continued active participation in lifestyle modifications
  • For continuation: BMI >= 18.5 kg/m2

Approval and renewal

  • Initial approval: 12 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight and For adults (obesity/CV risk reduction): 5% weight loss from baseline, current weight submission, attestation of continued active participation in lifestyle modifications, BMI >= 18.5 kg/m2. CV disease establishment and other initial criteria are not explicitly re-verified at continuation. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Cannot be used in combination with other weight loss products
  • Cannot be used in combination with other GLP-1 agonist-containing products

Policy note: The CV risk reduction pathway is explicitly listed as a separate qualification route for adults with established cardiovascular disease. The policy does not specify particular CV qualifying events (e.g., MI, stroke, PAD) beyond 'established cardiovascular disease.' No exclusion of patients with diabetes is stated. Continuation uses the same criteria as the obesity/overweight continuation pathway (5% weight loss from baseline).

Policy effective June 1, 2026 · verified June 2, 2026 · source: prior-authorization-and-step-therapy-guidelines.pdf

ACA Marketplace

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • BMI of 27 or higher with a weight-related condition (CVD)
  • Established cardiovascular disease (established_cardiovascular_disease)

Qualification pathways

You can qualify through any one of these.

CV Risk Reduction in Adults with Established CVD and Obesity/Overweight

All of:

  • Established cardiovascular disease
  • Obesity (BMI >= 30 kg/m2) OR overweight (BMI >= 27 kg/m2)
  • Used in combination with reduced calorie diet and increased physical activity
  • Current baseline weight documented
  • Physician attestation that member will participate in lifestyle modifications
  • Not to be used in combination with other weight loss products
  • Cannot be used in combination with other GLP-1 agonist-containing products

Documentation to bring

  • Documentation of established cardiovascular disease
  • Physician attestation of BMI >= 30 kg/m2 (obese) or >= 27 kg/m2 (overweight)
  • Documentation of current baseline weight
  • Physician attestation of member participation in lifestyle modifications (reduced calorie diet and increased physical activity)
  • Attestation that medication will not be combined with other weight loss products
  • Attestation that medication will not be combined with other GLP-1 agonist-containing products
  • For continuation: Physician attestation that member maintains >= 5% weight loss from baseline
  • For continuation: Current weight submission
  • For continuation: Attestation of continued active participation in lifestyle modifications
  • For continuation: BMI >= 18.5 kg/m2

Approval and renewal

  • Initial approval: 12 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight and For adults (obesity/CV risk reduction): 5% weight loss from baseline, current weight submission, attestation of continued active participation in lifestyle modifications, BMI >= 18.5 kg/m2. CV disease establishment and other initial criteria are not explicitly re-verified at continuation. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Cannot be used in combination with other weight loss products
  • Cannot be used in combination with other GLP-1 agonist-containing products

Policy note: The CV risk reduction pathway is explicitly listed as a separate qualification route for adults with established cardiovascular disease. The policy does not specify particular CV qualifying events (e.g., MI, stroke, PAD) beyond 'established cardiovascular disease.' No exclusion of patients with diabetes is stated. Continuation uses the same criteria as the obesity/overweight continuation pathway (5% weight loss from baseline).

Policy effective June 1, 2026 · verified June 2, 2026 · source: prior-authorization-and-step-therapy-guidelines.pdf

Wegovy for Liver Disease (MASH)

What BCBS Michigan requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 18 and older
  • Confirmed MASH diagnosis, fibrosis stage F2 to F3

Qualification pathways

You can qualify through any one of these.

MASH with Moderate to Advanced Liver Fibrosis (F2-F3)

All of:

  • Diagnosis of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH)
  • Moderate to advanced liver fibrosis consistent with stages F2 to F3
  • Adult (age >= 18 years old)
  • Current baseline weight documented
  • Used in combination with reduced calorie diet and increased physical activity
  • Physician attestation that member will participate in lifestyle modifications
  • Not to be used in combination with other weight loss products
  • Cannot be used in combination with other GLP-1 agonist-containing products

Documentation to bring

  • Documentation of diagnosis of noncirrhotic MASH with moderate to advanced liver fibrosis (F2 to F3)
  • Documentation of current baseline weight
  • Physician attestation of member participation in lifestyle modifications (reduced calorie diet and increased physical activity)
  • Attestation that medication will not be combined with other weight loss products
  • Attestation that medication will not be combined with other GLP-1 agonist-containing products
  • For continuation: Physician attestation of current weight submitted to plan
  • For continuation: Attestation of continued active participation in lifestyle modifications
  • For continuation: BMI >= 18.5 kg/m2

Approval and renewal

  • Initial approval: 12 months
  • To renew, the plan looks for For MASH continuation: Physician attestation of current weight submitted to plan, attestation of continued active participation in lifestyle modifications that support weight loss, BMI >= 18.5 kg/m2. No explicit weight loss percentage threshold required for MASH continuation (unlike obesity/CV pathways which require 5% weight loss).

Not covered when

  • Cirrhotic MASH is excluded (noncirrhotic only)
  • Cannot be used in combination with other weight loss products
  • Cannot be used in combination with other GLP-1 agonist-containing products

Policy note: The policy specifies noncirrhotic MASH only, with fibrosis stages F2 to F3. No specific fibrosis confirmation methods (biopsy, FibroScan, FIB-4, MRE, ELF) are specified in the policy. No lookback periods for diagnostic tests are specified. Continuation criteria for MASH differ from obesity/CV pathways — no explicit weight loss percentage threshold is required; instead physician attestation of current weight and continued lifestyle modifications are required along with BMI >= 18.5 kg/m2.

Policy effective June 1, 2026 · verified June 2, 2026 · source: prior-authorization-and-step-therapy-guidelines.pdf

ACA Marketplace

Covered with requirements

What you need to qualify

  • Age 18 and older
  • Confirmed MASH diagnosis, fibrosis stage F2 to F3

Qualification pathways

You can qualify through any one of these.

MASH with Moderate to Advanced Liver Fibrosis (F2-F3)

All of:

  • Diagnosis of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH)
  • Moderate to advanced liver fibrosis consistent with stages F2 to F3
  • Adult (age >= 18 years old)
  • Current baseline weight documented
  • Used in combination with reduced calorie diet and increased physical activity
  • Physician attestation that member will participate in lifestyle modifications
  • Not to be used in combination with other weight loss products
  • Cannot be used in combination with other GLP-1 agonist-containing products

Documentation to bring

  • Documentation of diagnosis of noncirrhotic MASH with moderate to advanced liver fibrosis (F2 to F3)
  • Documentation of current baseline weight
  • Physician attestation of member participation in lifestyle modifications (reduced calorie diet and increased physical activity)
  • Attestation that medication will not be combined with other weight loss products
  • Attestation that medication will not be combined with other GLP-1 agonist-containing products
  • For continuation: Physician attestation of current weight submitted to plan
  • For continuation: Attestation of continued active participation in lifestyle modifications
  • For continuation: BMI >= 18.5 kg/m2

Approval and renewal

  • Initial approval: 12 months
  • To renew, the plan looks for For MASH continuation: Physician attestation of current weight submitted to plan, attestation of continued active participation in lifestyle modifications that support weight loss, BMI >= 18.5 kg/m2. No explicit weight loss percentage threshold required for MASH continuation (unlike obesity/CV pathways which require 5% weight loss).

Not covered when

  • Cirrhotic MASH is excluded (noncirrhotic only)
  • Cannot be used in combination with other weight loss products
  • Cannot be used in combination with other GLP-1 agonist-containing products

Policy note: The policy specifies noncirrhotic MASH only, with fibrosis stages F2 to F3. No specific fibrosis confirmation methods (biopsy, FibroScan, FIB-4, MRE, ELF) are specified in the policy. No lookback periods for diagnostic tests are specified. Continuation criteria for MASH differ from obesity/CV pathways — no explicit weight loss percentage threshold is required; instead physician attestation of current weight and continued lifestyle modifications are required along with BMI >= 18.5 kg/m2.

Policy effective June 1, 2026 · verified June 2, 2026 · source: prior-authorization-and-step-therapy-guidelines.pdf

Why Wegovy requests get denied by BCBS Michigan

Based on what this policy asks for. Fix these before the first submission.

  1. Wrong brand for the diagnosis. Wegovy and Ozempic are the same molecule with different approved uses; a request for Wegovy under a diagnosis that matches Ozempic is routinely denied.
  2. BMI not documented in the chart notes (or documented without a baseline weight and date).
  3. Qualifying weight-related condition not documented with its own diagnosis code.
  4. Baseline weight wasn't recorded at the start, so the required weight loss can't be shown at renewal.

Frequently asked questions

Does BCBS Michigan cover Wegovy?
BCBS Michigan covers Wegovy for weight loss with prior authorization on Employer / Commercial Insurance and ACA Marketplace.
What BMI do you need for Wegovy under BCBS Michigan?
For weight loss on Employer / Commercial Insurance plans, BCBS Michigan requires a BMI of 30 or higher, or 27 or higher with a qualifying weight-related condition. Other plan types may differ — see each plan type below.
How long does a Wegovy approval last with BCBS Michigan?
Initial approvals last 12 months.
What does BCBS Michigan require to renew Wegovy?
At least 5% weight loss from the starting weight, at least 1% reduction in BMI, and For adults (obesity/overweight pathway): 5% weight loss from baseline, current weight submission, attestation of continued active participation in lifestyle modifications, BMI >= 18.5 kg/m2. For pediatrics (ages 12-17): 1% reduction in BMI from baseline, current weight submission, attestation of continued active participation in lifestyle modifications, BMI-for-age percentile >= 5th percentile. Initial BMI/comorbidity and other initial criteria are not explicitly re-verified at continuation.
How current is this information?
This page reflects BCBS Michigan's written policy as of June 1, 2026, last verified against the source document on June 2, 2026.

Other medications under BCBS Michigan

Wegovy coverage under other plans

All insurance plans · All medications

This page summarizes BCBS Michigan's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.